Agenus has filed a patent for antibodies that specifically bind to the human OX40 receptor (OX40) and can modulate its activity. The antibodies can enhance, activate, or induce OX40 activity for treating disorders like cancer, or reduce, deactivate, or inhibit OX40 activity for treating autoimmune or inflammatory diseases. GlobalData’s report on Agenus gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Agenus, personalized cancer vaccines was a key innovation area identified from patents. Agenus's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.
Antibodies for modulating ox40 activity in treating diseases
A recently filed patent (Publication Number: US20230167186A1) describes a method for detecting OX40 in a sample using a specific antibody. The method involves contacting the sample with an antibody that specifically binds to human OX40. The antibody consists of a variable heavy chain (VH) and a variable light chain (VL), each containing three complementarity-determining regions (CDRs).
In one embodiment of the invention, the VH of the antibody has amino acid sequences for CDR1, CDR2, and CDR3 that are specified in SEQ ID NO: 16, while the VL has amino acid sequences for CDR1, CDR2, and CDR3 specified in SEQ ID NO: 15.
The patent also describes various other embodiments of the antibody. For example, the antibody may have VH CDR1, CDR2, and CDR3 amino acid sequences specified in SEQ ID NOs: 4, 5, and 6, respectively, or VL CDR1, CDR2, and CDR3 amino acid sequences specified in SEQ ID NOs: 1, 2, and 3, respectively.
Additionally, the antibody may consist of a heavy chain and a light chain, with the heavy chain having amino acid sequences specified in SEQ ID NOs: 21, 23, 51, 52, 60, 61, 62, or 63, and the light chain having an amino acid sequence specified in SEQ ID NO: 20.
The antibody may also include a detectable label for easy detection.
Furthermore, the patent describes the antibody having a heavy chain constant region selected from human IgG1, IgG2, IgG3, IgG4, IgA1, or IgA2, and/or a light chain constant region selected from human IgG? or IgG?.
In certain embodiments, the heavy chain constant region may have specific amino acid mutations, such as N297A, N297Q, D265A, P329A, or a combination thereof for IgG1, an S228P mutation for IgG4, or a C127S mutation for IgG2, as numbered according to the EU index as in Kabat.
Overall, this patent provides a method for detecting OX40 using a specific antibody with defined amino acid sequences and constant regions, offering potential applications in diagnostic and therapeutic fields related to OX40 detection and modulation.
To know more about GlobalData’s detailed insights on Agenus, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
